Mylan Inc. has agreed to pay $57 million to resolve allegations that it fraudulently increased the reimbursement amount for its drugs by reporting inflated prices.  This case is one of several average wholesale price fraud cases brought by corporate whistleblower Ven-A-Care.  The whistle-blowing company has recovered over $3 billion for the federal government.

Read the entire article, “Mylan to Pay $57 Million to Settle Drug Overpricing Claims”